

# Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) - Drugs in Development, 2021

<https://marketpublishers.com/r/R45A0E4BE8BAEN.html>

Date: March 2021

Pages: 115

Price: US\$ 2,000.00 (Single User License)

ID: R45A0E4BE8BAEN

## Abstracts

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) - Drugs in Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Drugs in Development, 2021, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 9, 12, 3 and 5 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in  
Therapeutics Development

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development

Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Addpharma Inc, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cancer Advances Inc, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Changchun Serene Pharmaceutical Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cinclus Pharma AG, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hana Pharm Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by HK inno.N Corp, 2021

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hunan Mingrui

Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang  
Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by ISOThrive Inc,  
2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil  
Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jiangsu Carephar  
Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea Pharma Co  
Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea United  
Pharm Inc, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma  
Inc, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Renexxion LLC,  
2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sun Pharma  
Advanced Research Company Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda  
Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Trio Medicines Ltd,  
2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Xiamen Encheng  
Pharmaceutical Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by XuanZhu  
Biological Technology Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm  
Co Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yungjin Pharm Co  
Ltd, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2021  
(Contd..1)  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2021  
(Contd..2)  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2021  
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2021  
(Contd..1)





## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

## I would like to order

Product name: Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/R45A0E4BE8BAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R45A0E4BE8BAEN.html>